Cellular Intelligence Acquires Novo Nordisk Parkinson's Cell Therapy Program

Cellular Intelligence has obtained global rights to Novo Nordisk AS's clinical stage allogeneic cell therapy program for Parkinson's disease, announced in a press release. The therapy has received FDA Fast Track Designation and is currently in a Phase 1/2 clinical trial.

Cellular Intelligence plans to apply its AI foundation model to optimize and scale the program's development and manufacturing. The company aims to shorten traditional timelines and reduce costs to accelerate the path to commercialization. Novo Nordisk will become an equity investor in Cellular Intelligence and remains eligible for future milestone payments and royalties.

The cell therapy is derived from pluripotent stem cells and designed to produce dopaminergic progenitor cells for patients with Parkinson's disease. Cellular Intelligence will also appoint Nuno Mendonça, M.D., as Chief Medical Officer to lead clinical advancement of the program.

The company stated that data generated through this program will further train its AI foundation model, which it expects to apply across future cell therapy and regenerative medicine programs.